With Strong Humira Sales Growth, Abbott Is Bullish On Its Second-Quarter Results
This article was originally published in The Pink Sheet Daily
Executive Summary
The drug maker also reports rising sales for its dyslipidemia franchise.
You may also be interested in...
New Zealand's PHARMAC Gains $41 Million In Funding; Adds Sprycel And Humira For Reimbursement
PERTH, Australia - New Zealand's Pharmaceutical Management Agency's 2009/2010 budget saw a $41 million increase, bringing the total agency budget to $694 million, with $10 million of the new funds transferred from New Zealand District Health Board budgets
J&J's Intravenous Remicade Grows Despite Tough Times
Implications for anti-TNFs Humira and Enbrel, which tumbled in the first quarter, are unclear.
AstraZeneca To Co-Promote Abbott’s TriLipix; NDA Is Filed For Crestor/TriLipix
AstraZeneca and Abbott announce co-promotion agreement for TriLipix ahead of an FDA decision on a jointly-developed investigational Crestor/TriLipix compound.